Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 50%Low 0 · 0%Moderate 1 · 50%High 0 · 0%

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.56 [0.5, 0.63]
3 studies · 1564 participants
Moderate

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Progression‐free survival · newly‐diagnosed EOC

It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
HR 0.82 [0.64, 1.05]
2 studies · 2746 participants
Very low